Revvity Inc. $RVTY Shares Sold by Swiss National Bank

Swiss National Bank reduced its position in Revvity Inc. (NYSE:RVTY) by 2.0% in the 1st quarter, Holdings Channel reports. The fund owned 224,300 shares of the company’s stock after selling 4,600 shares during the period. Swiss National Bank’s holdings in Revvity were worth $19,651,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ascentis Independent Advisors acquired a new stake in shares of Revvity in the first quarter worth approximately $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity in the second quarter worth about $32,000. Cromwell Holdings LLC boosted its holdings in Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after acquiring an additional 198 shares during the period. MUFG Securities EMEA plc purchased a new stake in Revvity during the 2nd quarter worth $34,000. Finally, Headlands Technologies LLC purchased a new position in Revvity in the 2nd quarter valued at about $49,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RVTY has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Stifel Nicolaus decreased their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research report on Wednesday, May 6th. Zacks Research cut shares of Revvity from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Finally, Wolfe Research assumed coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $108.92.

Revvity Stock Down 2.3%

Shares of Revvity stock opened at $110.56 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company has a market cap of $12.33 billion, a P/E ratio of 52.90, a P/E/G ratio of 2.23 and a beta of 1.09. The stock has a 50-day moving average price of $104.90 and a 200 day moving average price of $99.61. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $118.30.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. Revvity’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, analysts expect that Revvity Inc. will post 5.25 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s dividend payout ratio (DPR) is currently 13.40%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.